VEGFA and neoplasm: As an anti-vascular endothelial growth factor (VEGF) monoclonal antibody, bevacizumab exerts its efficacy by inhibiting VEGF-mediated tumor angiogenesis, thereby alleviating compressive symptoms such as hearing loss.